Combination of the new minor groove alkylator tallimustine and melphalanTAGLIABUE, G; FILIPPINI, C; UBEZIO, P et al.European journal of cancer (1990). 1997, Vol 33, Num 2, pp 284-287, issn 0959-8049Article

DNA sequence-recognizing properties of minor groove alkylating agents : Effects of the replacement of N-methylpyrrole by an n-methylimidazole on tallimustine and its own homologueBARALDI, P. G; ROMAGNOLI, R; SPALLUTO, G et al.Arzneimittel-Forschung. 2000, Vol 50, Num 3, pp 309-315, issn 0004-4172Article

The alkylating antitumor drug tallimustine does not induce DNA repairROSSI, R; MONTECUCCO, A; CAPOLONGO, L et al.Anticancer research. 1996, Vol 16, Num 6B, pp 3779-3783, issn 0250-7005Article

A phase I and pharmacokinetic study of tallimustine [PNU152241 (FCE 24517)] in patients with advanced cancerWEISS, G. R; POGGESI, I; O'DWYER, P et al.Clinical cancer research. 1998, Vol 4, Num 1, pp 53-59, issn 1078-0432Article

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cellsGHIELMINI, M; BOSSHARD, G; CAPOLONGO, L et al.British journal of cancer. 1997, Vol 75, Num 6, pp 878-883, issn 0007-0920Article

Accumulation of γ-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustineBIANCHI, Nicoletta; CHIARABELLI, Cristiano; BORGATTI, Monica et al.British journal of haematology. 2001, Vol 113, Num 4, pp 951-961, issn 0007-1048Article

Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agentsFILIPPINI, C; BISIACH, M; TAGLIABUE, G et al.International journal of cancer. 1997, Vol 72, Num 5, pp 801-809, issn 0020-7136Article

Determination of tallimustine in human plasma by high-performance liquid chromatographyMAMMARI, P; PIANEZZOLA, E; BENEDETTI, M. S et al.Journal of chromatography. B, Biomedical applications. 1996, Vol 677, Num 1, pp 133-139Article

The mutagenic properties of DNA minor-groove binding ligandsTURNER, P. R; DENNY, W. A.Mutation research. 1996, Vol 355, Num 1-2, pp 141-169, issn 0027-5107Article

Phase I study of the novel distamycin derivative tallimustine (FCE 24517)SESSA, C; PAGANI, O; ZURLO, M. G et al.Annals of oncology. 1994, Vol 5, Num 10, pp 901-907, issn 0923-7534Article

Tallimustine in advanced previously untreated colorectal cancer, a phase II studyPUNT, C. J. A; HUMBLET, Y; ROCA, E et al.British journal of cancer. 1996, Vol 73, Num 6, pp 803-804, issn 0007-0920Article

Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell lineERBA, E; MASCELLANI, E; PIFFERI, A et al.International journal of cancer. 1995, Vol 62, Num 2, pp 170-175, issn 0020-7136Article

Cytotoxics derived from distamycin A and congenersCOZZI, P; MONGELLI, N.Current pharmaceutical design. 1998, Vol 4, Num 3, pp 181-201, issn 1381-6128Article

Cinnamoyl nitrogen mustard derivatives of pyrazole analogues of tallimustine modified at the amidino moiety: design, synthesis, molecular modeling and antitumor activity studiesBARALDI, Pier Giovanni; BERIA, Italo; COZZI, Paolo et al.Bioorganic & medicinal chemistry. 2004, Vol 12, Num 14, pp 3911-3921, issn 0968-0896, 11 p.Article

Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin ABARALDI, P. G; ROMAGNOLI, R; BERIA, I et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 14, pp 2675-2684, issn 0022-2623Article

A new class of cytotoxic DNA minor groove binders : α-halogenoacrylic derivatives of pyrrolecarbamoyl oligomersCOZZI, Paolo.Il Farmaco (Pavia). 2001, Vol 56, Num 1-2, pp 57-65, issn 0014-827XConference Paper

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine)CIOMEI, M; PASTORI, W; CAPOLONGO, L et al.British journal of cancer. 1995, Vol 72, Num 6, pp 1504-1508, issn 0007-0920Article

Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: Synthesis and antitumour activityBARALDI, Pier Giovanni; ROMAGNOLI, Romeo; PAVANI, Maria Giovanna et al.Bioorganic & medicinal chemistry. 2002, Vol 10, Num 5, pp 1611-1618, issn 0968-0896Article

Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I studyBERAN, M; JEHA, S; O'BRIEN, S et al.Clinical cancer research. 1997, Vol 3, Num 12, pp 2377-2384, issn 1078-0432, 1Article

Synthesis of an aminopropyl analog of the experimental anticancer drug tallimustine, and activation of its 4-nitrobenzylcarbamoyl prodrug by nitroreductase and NADHLEE, M; SIMPSON, J. E; WOO, S et al.Bioorganic & medicinal chemistry letters (Print). 1997, Vol 7, Num 8, pp 1065-1070, issn 0960-894XArticle

Sequence-specific DNA alkylation of novel tallimustine derivativesMARCHINI, S; COZZI, P; BERIA, I et al.Anti-cancer drug design. 1998, Vol 13, Num 3, pp 193-205, issn 0266-9536Article

PNU 157977 : a new potent antitumour agent exhibiting low in vivo toxicity in mice injected with L1210 leukaemia cellsBARALDI, P. G; BALBONI, G; ROMAGNOLI, R et al.Anti-cancer drug design. 1999, Vol 14, Num 1, pp 71-76, issn 0266-9536Article

The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site sizeBROOKS, N; MCHUGH, P. J; LEE, M et al.Anti-cancer drug design. 1999, Vol 14, Num 1, pp 11-18, issn 0266-9536Article